DAY ONE BIOPHARMACEUTICALS I (DAWN)

US23954D1090 - Common Stock

16.52  +0.73 (+4.62%)

After market: 16.52 0 (0%)

News Image
a month ago - Seeking Alpha

Day One Biopharmaceuticals reports Q4 results (NASDAQ:DAWN)

Day One Biopharmaceuticals reported a Q4 net loss of $54.5 million and ended 2023 with $366.3 million in cash, ensuring financial stability until 2026.

News Image
a month ago - Day One Biopharmaceuticals, Inc.

Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress

PDUFA target action date for tovorafenib NDA in relapsed or progressive pLGG remains set for April 30, 2024 Phase 2 FIREFLY-1 tovorafenib registrational...

News Image
2 months ago - Day One Biopharmaceuticals, Inc.

Day One Announces Two New Appointments to Board of Directors

News Image
3 months ago - Day One Biopharmaceuticals, Inc.

Day One to Present at the 42nd Annual J.P. Morgan Healthcare Conference

BRISBANE, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a clinical-stage...

News Image
4 months ago - Day One Biopharmaceuticals, Inc.

Day One Announces Tovorafenib FIREFLY-1 Data Published in Nature Medicine

Data subsets to be shared today in plenary oral presentations at the 2023 Society for Neuro-Oncology Annual Meeting

News Image
4 months ago - Day One Biopharmaceuticals, Inc.

Day One Announces Tovorafenib FIREFLY-1 Data Published in Nature Medicine

Data subsets to be shared today in plenary oral presentations at the 2023 Society for Neuro-Oncology Annual Meeting...

News Image
5 months ago - Seeking Alpha

Day One stock rallies 20% on FDA update for brain tumor drug (NASDAQ:DAWN)

Day One stock surged 20% on news that the FDA had accepted its New Drug Application for tovorafenib and doesn't plan to hold an advisory committee meeting on the drug. Read more.

News Image
5 months ago - Day One Biopharmaceuticals, Inc.

Day One Announces FDA Acceptance of NDA and Priority Review for Tovorafenib in Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)

Priority review granted with PDUFA target action date of April 30, 2024

News Image
5 months ago - Day One Biopharmaceuticals, Inc.

Day One Announces FDA Acceptance of NDA and Priority Review for Tovorafenib in Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)

The FDA has granted priority review and assigned a Prescription Drug User Fee Act (PDUFA) target action date of April 30, 2024. ...

News Image
7 months ago - Seeking Alpha

Day One Biopharmaceuticals launches mixed shelf offering - filing (NASDAQ:DAWN)

Day One Biopharmaceuticals (DAWN) disclosed in a Securities and Exchange Filing on Thursday a prospectus for a mixed shelf offering, size undisclosed. Under the offering, the company...

News Image
7 months ago - Day One Biopharmaceuticals, Inc.

Day One Announces Updated FIREFLY-1 Data for Tovorafenib and Completion of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)

Overall response rate (ORR) greater than 50% across three assessment criteria Median duration of tovorafenib treatment of 15.8 months as of June 5, 2023,...

News Image
7 months ago - Day One Biopharmaceuticals, Inc.

Day One Announces Updated FIREFLY-1 Data for Tovorafenib and Completion of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)

Overall response rate (ORR) greater than 50% across three assessment criteria Median duration of tovorafenib treatment of 15.8 months as of June 5, 2023,...

News Image
8 months ago - Day One Biopharmaceuticals, Inc.

Day One Reports Second Quarter 2023 Financial Results and Corporate Progress

Results from FIREFLY-1 demonstrate overall response rate (ORR) of 67% and clinical benefit rate (CBR) of 93% in 69 heavily pretreated Response Assessment...

News Image
10 months ago - Day One Biopharmaceuticals, Inc.

Day One Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

BRISBANE, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated...

News Image
10 months ago - Investor's Business Daily

Stock Market Rally Broadens Out; Apple Unveils Vision Pro, SEC Sues Binance, Coinbase: Weekly Review

The Nasdaq held near 52-week highs while small caps ramped up.